• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Cytogen launches brachytherapy product

Article

Radiopharmaceutical developer Cytogen has commercially released a new brachytherapy implant for the treatment of localized prostate cancer. DraxImage, the radiopharmaceutical subsidiary of Draxis Health, developed the next-generation radioactive seed,

Radiopharmaceutical developer Cytogen has commercially released a new brachytherapy implant for the treatment of localized prostate cancer. DraxImage, the radiopharmaceutical subsidiary of Draxis Health, developed the next-generation radioactive seed, called BrachySeed Palladium-103. This is the second such offering by Cytogen and DraxImage. The first, BrachySeed I-125 containing radioactive iodine, was launched in 2001. The BrachySeed products complement Cytogen's ProstaScint, a monoclonal antibody-based agent used to image the extent and spread of prostate cancer.

Recent Videos
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Teleradiology and Breast Imaging: Keys to Facilitating Personalized Service, Efficiency and Equity
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 2
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, Part 1
Addressing Cybersecurity Issues in Radiology
Computed Tomography Study Shows Emergence of Silicosis in Engineered Stone Countertop Workers
Can an Emerging AI Software for DBT Help Reduce Disparities in Breast Cancer Screening?
Related Content
© 2025 MJH Life Sciences

All rights reserved.